SUNDAY, SEPTEMBER 25, 2016

Merck will continue to support AIDS Drug Assistance Programs

Merck announced on July 29 that it will continue to support state AIDS Drug Assistance Programs through December 31, 2014.

In the new deal, Merck will provide continued support for initiatives to provide low-income individuals living with HIV with access to medicines. Merck will also give access for eligible ADAPs to obtain ISENTRESS film-coated tablets at the January 2012 price. Finally, Merck will add a "frozen" low price to eligible ADAPs for ISENTRESS chewable tablets for the treatment of HIV-1 infection in children and adolescents two years of age and older.

"Merck has steadfastly supported the ACTF since 2002. We are proud to reaffirm our long-standing commitment to ADAPs and their mission to help people living with HIV," Chirfi Guindo, vice president and general manager of Merck, said. "ADAPs continue to experience fiscal instability as a result of a changing healthcare system. By working together as partners - government, community and industry - we can help to support these critical state programs, and help provide access to medicines for uninsured and underserved HIV patients."

ADAPs are estimated to reach about one-third of people with HIV in the United States. Merck has contributed to the ADAP program 3 other times in the past and was also the first company to freeze the price of an antiretroviral therapy.

ISENTRESS is an integrase inhibitor used to treat and control HIV-1. ISENTRESS does not cure HIV-1 or AIDS.